Arena Pharmaceuticals (NASDAQ:ARNA) will be issuing its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($1.02) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Arena Pharmaceuticals (NASDAQ:ARNA) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $12.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $12.91. Arena Pharmaceuticals had a return on equity of 69.72% and a net margin of 76.19%. The company had revenue of $801.06 million for the quarter, compared to analyst estimates of $801.82 million. During the same quarter in the prior year, the firm posted ($0.80) EPS. Arena Pharmaceuticals’s quarterly revenue was up 45414.8% compared to the same quarter last year. On average, analysts expect Arena Pharmaceuticals to post $9 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
NASDAQ:ARNA opened at $60.06 on Monday. The firm’s fifty day moving average is $60.14. Arena Pharmaceuticals has a fifty-two week low of $31.97 and a fifty-two week high of $64.48. The stock has a market cap of $2.98 billion, a price-to-earnings ratio of -20.36 and a beta of 1.42. The company has a quick ratio of 35.51, a current ratio of 35.51 and a debt-to-equity ratio of 0.04.
In other Arena Pharmaceuticals news, Director Jayson Donald Alexander Dallas sold 1,525 shares of the company’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $55.90, for a total value of $85,247.50. Following the transaction, the director now owns 5,704 shares of the company’s stock, valued at approximately $318,853.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.73% of the company’s stock.
Several analysts recently weighed in on ARNA shares. BidaskClub upgraded Arena Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday. Zacks Investment Research lowered Arena Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 15th. TheStreet raised Arena Pharmaceuticals from a “c” rating to a “b” rating in a research report on Friday, May 31st. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Arena Pharmaceuticals in a research report on Wednesday, May 8th. Finally, ValuEngine downgraded Arena Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $62.17.
Arena Pharmaceuticals Company Profile
Arena Pharmaceuticals, Inc, a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain.
Further Reading: Cost of Goods Sold (COGS)
Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.